[{"id":"ad97f5e4-fc89-4bc4-8a29-5f1e8e93233f","acronym":"QUASAR","url":"https://clinicaltrials.gov/study/NCT02446795","created_at":"2021-01-18T11:43:40.234Z","updated_at":"2024-07-02T16:37:26.445Z","phase":"Phase 1/2","brief_title":"Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial","source_id_and_acronym":"NCT02446795 - QUASAR","lead_sponsor":"Consorzio Oncotech","biomarkers":" IL6 • IL10","pipe":"","alterations":" ","tags":["IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Kinisoquin (isoquercetin)"],"overall_status":"Unknown status","enrollment":" Enrollment 104","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2017-01-18"}]